Respiratory syncytial virus vaccine

A technology for syncytial virus and respiratory tract, which can be applied in the directions of viruses, vaccines, antiviral agents, etc., and can solve the problems of tumor suppressor gene inhibition, insertional mutagenesis, oncogene activation, etc.

Pending Publication Date: 2018-08-31
MODERNATX INC
View PDF156 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, potential issues arise with this technique, including the possibility of insertional

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Respiratory syncytial virus vaccine
  • Respiratory syncytial virus vaccine
  • Respiratory syncytial virus vaccine

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0287] The formulation of the vaccine composition described herein can be prepared by any method known or later developed in pharmacological technology. Generally, such preparation methods include the following steps: associating active ingredients (for example, mRNA polynucleotides) with excipients and / or one or more other auxiliary ingredients, and then, when necessary and / or required , The product is divided, shaped and / or packaged into the required single or multiple dose units.

[0288] According to the present disclosure, the relative amounts of the active ingredients, pharmaceutically acceptable excipients and / or any other ingredients in the pharmaceutical composition will be based on the identity, body type and / or condition of the subject to be treated and further based on the composition. The route of administration varies. For example, the composition may comprise between 0.1% and 100%, such as between 0.5 and 50%, between 1 and 30%, between 5 and 80%, at least 80% ( ...

Embodiment approach

[0463] 1. A respiratory syncytial virus (RSV) vaccine, which comprises:

[0464] At least one messenger ribonucleic acid (mRNA) polynucleotide having a 5'end cap, an open reading frame encoding at least one RSV antigenic polypeptide, and a 3'polyA tail.

[0465] 2. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by the sequence identified by SEQ ID NO:257.

[0466] 3. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by the sequence identified by SEQ ID NO:258.

[0467] 4. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by the sequence identified by SEQ ID NO:259.

[0468] 5. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises the sequence identified by SEQ ID NO:278.

[0469] 6. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises the sequence identified by SEQ ID NO:279.

[0470] 7. The vaccine of paragraph 1, wherein the ...

Embodiment 1

[0501] Example 1: Production of polynucleotide

[0502] According to the present disclosure, the method taught in International Publication WO2014 / 152027 entitled "Manufacturing Methods for Production of RNATranscripts" can be used to achieve the production of polynucleotides and / or parts or regions thereof. The content of this patent is incorporated by reference. Incorporated into this article.

[0503] The purification method may include those methods taught in International Publication WO2014 / 152030 and International Publication WO2014 / 152031, and each patent is incorporated herein by reference in its entirety.

[0504] The method of polynucleotide detection and characterization can be carried out as taught in International Publication WO2014 / 144039, which is incorporated herein by reference in its entirety.

[0505] The characterization of the polynucleotides of the present disclosure can be achieved using polynucleotide mapping, reverse transcriptase sequencing, charge distributi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Description

[0001] Related application [0002] This application requires U.S. Provisional Application No. 62 / 245,208 filed on October 22, 2015, U.S. Provisional Application No. 62 / 247,563 filed on October 28, 2015 and October 2015 in accordance with 35U.SC §119(e) U.S. Provisional Application No. 62 / 248,250 filed on the 29th, each provisional application is incorporated herein by reference in its entirety. This application also claims the benefits of U.S. Provisional Application No. 62 / 245,031 filed on October 22, 2015 under 35 U.S.C. §119(e), which is incorporated herein by reference in its entirety. Background technique [0003] Human Respiratory Syncytial Virus (RSV) is an antisense single-stranded RNA virus of the subfamily Pneumovirinae and Paramyxoviridae. Symptoms in adults are usually similar to sinus infections or the common cold, but infections may also be asymptomatic. In elderly adults (eg, >60 years old), RSV infection may progress to bronchiolitis or pneumonia. Symptoms in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/155A61K31/7105A61K31/7115A61P31/14C12N15/11
CPCA61K31/7105A61K31/7115A61K2039/53A61K2039/55555C12N2760/18534A61K39/12A61P31/14Y02A50/30A61K39/155A61K2039/6018A61K2039/5254A61K2039/5252A61K2039/54A61K2039/545A61K2039/70
Inventor 朱塞佩·恰拉梅拉卡皮尔·巴尔埃米·埃斯佩塞特D·王安德鲁·J·贝特
Owner MODERNATX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap